Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions

Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar M, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson SG, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade M, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood Adv. 2023 Apr 7:bloodadvances.2023010016. doi: 10.1182/bloodadvances.2023010016. Epub ahead of print. PMID: 37026796.


Related Posts